8-K: Marizyme and Qualigen Partner to Commercialize DuraGraft in US Market

Marizyme and Qualigen have entered into a co-development agreement to commercialize Marizyme's DuraGraft product in the U.S., with Qualigen providing up to $1.5 million in funding.

Summary

• Marizyme and Qualigen have entered into a co-development agreement focused on the commercialization of Marizyme's DuraGraft product in the United States.
• Qualigen will provide up to $1.5 million in funding to support the commercial launch of DuraGraft, including post-clearance clinical studies.
• In return for the funding, Qualigen will receive 33% of Marizyme's net sales of DuraGraft, capped at two times the invested capital.
• The agreement includes an exclusivity period until May 31, 2024, for Qualigen to propose a broader strategic relationship with Marizyme.
• Marizyme's DuraGraft is an FDA-cleared vascular conduit solution for use in coronary artery bypass grafting (CABG) surgeries.
• The U.S. market for CABG procedures is estimated to be over 500,000 annually, representing a significant opportunity for DuraGraft.

Sentiment

Score: 8

Explanation: The document reflects a positive development for both companies, with a clear path to commercialization and revenue generation. The terms of the agreement are reasonable and the potential market is significant.

Positives

• The agreement provides Marizyme with non-dilutive funding to accelerate the commercialization of DuraGraft.
• Qualigen gains access to a commercial-ready, FDA-cleared product with a clear path to revenue generation.
• The partnership allows both companies to leverage their respective strengths in medical technology and therapeutics.
• The exclusivity period provides Qualigen with an opportunity to explore a deeper strategic relationship with Marizyme.

Negatives

• The agreement caps Qualigen's return at two times their investment, limiting potential upside.
• Marizyme is obligated to pay Qualigen 33% of net sales, which could impact their profitability.
• The agreement is subject to termination by either party with 30 days written notice, which could create uncertainty.

Risks

• The commercialization of DuraGraft may face challenges, including pricing, marketing, and competition.
• Marizyme may require additional funding beyond the $1.5 million from Qualigen to fully commercialize DuraGraft.
• There are potential risks associated with the use of DuraGraft, including safety concerns and regulatory delays.
• The strategic relationship between the two companies may not materialize beyond the exclusivity period.

Future Outlook

The agreement is intended to support the commercial launch of DuraGraft in the U.S. market, with potential for a broader strategic relationship between the two companies. Marizyme aims to drive further utilization and sales of DuraGraft in the U.S. market. Qualigen anticipates revenue generation in the short term from this project.

Management Comments

• David Barthel, CEO of Marizyme, stated that this is an exciting opportunity to accelerate the commercialization of DuraGraft and build a strategic relationship with Qualigen.
• Michael Poirier, CEO of Qualigen, stated that this agreement provides Qualigen with participation in an FDA-cleared commercialization project with a visible path to revenue generation in the short term and allows flexibility to broaden the relationship.

Industry Context

This agreement reflects a trend of pharmaceutical and medical device companies collaborating to bring innovative products to market. The partnership leverages Qualigen's financial resources and commercial experience with Marizyme's innovative medical device technology. The focus on the CABG market aligns with the ongoing need for improved solutions in cardiac care.

Comparison to Industry Standards

• The co-development agreement structure is common in the biotech and medical device industries, where companies often partner to share the costs and risks of commercializing new products.
• The 2X return cap on Qualigen's investment is a typical arrangement in such agreements, balancing risk and reward.
• The 33% royalty on net sales is within the range of industry standards for licensing and co-development deals.
• The exclusivity period is a standard practice to allow for further negotiations and strategic planning.
• The focus on the U.S. market for CABG procedures is consistent with the large market opportunity for medical devices in this area.
• The agreement is similar to other partnerships where a larger company provides funding and commercialization expertise to a smaller company with innovative technology, such as the partnership between Medtronic and Mazor Robotics.

Stakeholder Impact

• Shareholders of both Marizyme and Qualigen may see a positive impact from the potential revenue generation and strategic partnership.
• Employees of Marizyme may benefit from the increased resources and commercialization efforts.
• Customers (hospitals and surgeons) may benefit from the availability of DuraGraft in the U.S. market.
• Suppliers of Marizyme may see increased demand for their products and services.
• Creditors of both companies may see improved financial stability due to the potential revenue generation.

Next Steps

• Qualigen will provide the agreed-upon funding to Marizyme.
• Marizyme will work towards the commercial launch of DuraGraft in the U.S.
• Qualigen and Marizyme will explore a broader strategic relationship during the exclusivity period.
• Marizyme will transfer the assets related to DuraGraft to a wholly owned subsidiary within 90 days of the effective date.

Key Dates

Keywords

DuraGraft, Marizyme, Qualigen, co-development agreement, vascular conduit, CABG, FDA clearance, commercialization, funding, strategic relationship